Source comparison
MOTS-c Aging Metabolism Results Timeline: Dosing Protocol Comparison
Daily 5mg/kg subcutaneous (preclinical standard) 28–34% improvement in glucose tolerance, AMPK activation within 48 hours 22% increase in mitochondrial content, 31% endurance improvement, reduced inflammatory markers Most cited protocol in published trials; su
This comparison does not assign a generated winner or score.
- Daily 5mg/kg subcutaneous (preclinical standard)
- 28–34% improvement in glucose tolerance, AMPK activation within 48 hours
- 22% increase in mitochondrial content, 31% endurance improvement, reduced inflammatory markers
- Most cited protocol in published trials; subcutaneous administration avoids first-pass metabolism
- Gold standard for mechanistic research. Highest consistency across outcomes
- Intermittent 10mg/kg 3× weekly
- 18–22% improvement in glucose tolerance, less sustained AMPK activation
- Moderate mitochondrial gains (12–15%), endurance improvements plateau earlier
- Lower dosing frequency may reduce cumulative AMPK signaling
- Useful for models exploring minimum effective dose. Outcomes less robust than daily protocols
- High-dose 15mg/kg daily
- Similar acute glucose improvements, potential receptor saturation
- Diminishing returns on mitochondrial biogenesis, no additional endurance benefit vs 5mg/kg
- Higher doses do not linearly increase outcomes; may indicate receptor-mediated ceiling
- Not recommended. No clear benefit over standard 5mg/kg dosing, increased compound cost
- Oral administration (experimental)
- Minimal acute metabolic response, degraded by digestive enzymes
- No measurable mitochondrial or endurance outcomes
- Peptide structure unstable in gastric environment; bioavailability near zero
- Not viable for research. MOTS-c requires parenteral administration
- MOTS-c aging metabolism results timeline expect varies significantly with dosing frequency and peptide quality. Daily subcutaneous protocols at 5mg/kg body weight consistently outperform intermittent or oral routes across published research. Peptide purity matters. Compounds synthesized without rigorous quality control show reduced AMPK activation even at correct doses.